GlaxoSmithKline To Pay $105 Million for Promoting Off-Label Drug Use
In 2012, the pharmaceutical giant GlaxoSmithKline was forced to pay $3 billion in civil and criminal penalties for promoting its antidepressant drugs for off-label use. The penalties included $1 billion for hiding evidence that one of its drugs, Paxil, may cause birth defects. According to the Bloomberg article which covered the affair in detail, Glaxo is prohibited from providing incentive payments to salespeople that encourage uses not indicated on the drug labels. Glaxo also agreed to not provide any marketing materials that offer inaccurate information about its products. The agreement covers the depression drugs Paxil and Wellbutrin, as well as the asthma drug Advair.
Contact Mark Abramson:
1-800-662-6230 or abramson@arbd.com
1-800-662-6230 or abramson@arbd.com
Latest posts by Mark Abramson (see all)
- Significant Verdict: Family Receives $2 Million in Wrongful Death Suit - November 25, 2024
- Study Suggests Depressed Physicians Have Higher Risk of Making Medical Errors - January 3, 2020
- Prevalence of Stroke in Younger Adults Steadily Rising, According to 2017 Study - August 21, 2018
